3. Significant Strategic Drug Development Collaborations |
3 Months Ended | ||
|---|---|---|---|
Mar. 31, 2018 | |||
| Significant Strategic Drug Development Collaborations | |||
| Significant Strategic Drug Development Collaborations ? Related Parties |
The Company has entered into various research, development, license and supply agreements with Shire plc (“Shire”), Serum Institute of India (“Serum Institute”), its controlling stockholder PJSC Pharmsynthez (“Pharmsynthez”) and SynBio LLC (“SynBio”), which is now a wholly owned subsidiary of Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through March 31, 2018. No amounts were recognized as revenue related to these agreements during the three months ended March 31, 2018 or 2017. |